191 related articles for article (PubMed ID: 18032922)
1. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells.
Tyler RK; Shpiro N; Marquez R; Eyers PA
Cell Cycle; 2007 Nov; 6(22):2846-54. PubMed ID: 18032922
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells.
Xu DR; Huang S; Long ZJ; Chen JJ; Zou ZZ; Li J; Lin DJ; Liu Q
J Transl Med; 2011 May; 9():74. PubMed ID: 21600017
[TBL] [Abstract][Full Text] [Related]
3. Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells.
Pan C; Yan M; Yao J; Xu J; Long Z; Huang H; Liu Q
Oral Oncol; 2008 Jul; 44(7):639-45. PubMed ID: 17996488
[TBL] [Abstract][Full Text] [Related]
4. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia.
Huang XF; Luo SK; Xu J; Li J; Xu DR; Wang LH; Yan M; Wang XR; Wan XB; Zheng FM; Zeng YX; Liu Q
Blood; 2008 Mar; 111(5):2854-65. PubMed ID: 18160664
[TBL] [Abstract][Full Text] [Related]
5. Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells.
D'Alise AM; Amabile G; Iovino M; Di Giorgio FP; Bartiromo M; Sessa F; Villa F; Musacchio A; Cortese R
Mol Cancer Ther; 2008 May; 7(5):1140-9. PubMed ID: 18483302
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition.
Huang M; Feng X; Su D; Wang G; Wang C; Tang M; Paulucci-Holthauzen A; Hart T; Chen J
Oncogene; 2020 May; 39(21):4312-4322. PubMed ID: 32300176
[TBL] [Abstract][Full Text] [Related]
7. Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.
Kwiatkowski N; Deng X; Wang J; Tan L; Villa F; Santaguida S; Huang HC; Mitchison T; Musacchio A; Gray N
ACS Chem Biol; 2012 Jan; 7(1):185-96. PubMed ID: 21992004
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
[TBL] [Abstract][Full Text] [Related]
9. Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks.
Scutt PJ; Chu ML; Sloane DA; Cherry M; Bignell CR; Williams DH; Eyers PA
J Biol Chem; 2009 Jun; 284(23):15880-93. PubMed ID: 19359241
[TBL] [Abstract][Full Text] [Related]
10. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells.
Kaestner P; Stolz A; Bastians H
Mol Cancer Ther; 2009 Jul; 8(7):2046-56. PubMed ID: 19584233
[TBL] [Abstract][Full Text] [Related]
11. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.
Gizatullin F; Yao Y; Kung V; Harding MW; Loda M; Shapiro GI
Cancer Res; 2006 Aug; 66(15):7668-77. PubMed ID: 16885368
[TBL] [Abstract][Full Text] [Related]
12. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
13. Validating Aurora B as an anti-cancer drug target.
Girdler F; Gascoigne KE; Eyers PA; Hartmuth S; Crafter C; Foote KM; Keen NJ; Taylor SS
J Cell Sci; 2006 Sep; 119(Pt 17):3664-75. PubMed ID: 16912073
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.
Cheetham GM; Charlton PA; Golec JM; Pollard JR
Cancer Lett; 2007 Jun; 251(2):323-9. PubMed ID: 17240048
[TBL] [Abstract][Full Text] [Related]
15. Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.
Massey AJ; Borgognoni J; Bentley C; Foloppe N; Fiumana A; Walmsley L
PLoS One; 2010 Oct; 5(10):e13123. PubMed ID: 20976184
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Aurora-A results in increased cell death in 3-dimensional culture microenvironment, reduced migration and is associated with enhanced radiosensitivity in human nasopharyngeal carcinoma.
Wan XB; Fan XJ; Chen MY; Xu J; Long ZJ; Hua YJ; Ji H; Liu L; Hong MH; Zeng YX; Liu Q
Cancer Biol Ther; 2009 Aug; 8(15):1500-6. PubMed ID: 19502819
[TBL] [Abstract][Full Text] [Related]
17. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
[TBL] [Abstract][Full Text] [Related]
18. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity.
LeRoy PJ; Hunter JJ; Hoar KM; Burke KE; Shinde V; Ruan J; Bowman D; Galvin K; Ecsedy JA
Cancer Res; 2007 Jun; 67(11):5362-70. PubMed ID: 17545617
[TBL] [Abstract][Full Text] [Related]
19. Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues.
Ulisse S; Baldini E; Toller M; Delcros JG; Guého A; Curcio F; De Antoni E; Giacomelli L; Ambesi-Impiombato FS; Bocchini S; D'Armiento M; Arlot-Bonnemains Y
Endocr Relat Cancer; 2007 Sep; 14(3):827-37. PubMed ID: 17914111
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the aurora kinases suppresses in vitro NT2-D1 cell growth and tumorigenicity.
Ulisse S; Arlot-Bonnemains Y; Baldini E; Morrone S; Carocci S; Di Luigi L; D'Armiento M
J Endocrinol; 2010 Feb; 204(2):135-42. PubMed ID: 19889886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
